HylaPharm Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Private

  • Employees
  • 7


  • Latest Deal Type
  • Angel

  • Latest Deal Amount
  • $800K

  • Investors
  • 1

HylaPharm General Information


Developer of targeted cancer therapies and cancer drugs designed for dog treatment. The company specializes in the research and development of new cancer drugs for chemotherapeutic use, enabling pet families with customer clinical expertise and progressive treatment options.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly Angel backed
Primary Industry
Drug Discovery
Other Industries
Corporate Office
  • 2029 Becker Drive
  • Suite 285
  • Lawrence, KS 66047
  • United States
+1 (785) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

HylaPharm Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Angel (individual) 01-Oct-2015 $800K 00.00 Completed Product In Beta Test
2. Angel (individual) 16-Dec-2013 00000 00000 Completed Startup
1. Grant 22-Jan-2013 $200K Completed Startup
To view HylaPharm’s complete valuation and funding history, request access »

HylaPharm Patents

HylaPharm Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220177472-A1 Imidazoquinoline compounds and prodrugs thereof Pending 17-Apr-2019 0000000000
US-20200330507-A1 Platinum(iv) conjugates and methods of use Active 17-Apr-2019 0000000000
US-11458163-B2 Platinum(iv) conjugates and methods of use Active 17-Apr-2019 A61K33/243 0

HylaPharm Executive Team (5)

Name Title Board Seat Contact Info
Daniel Aires MD Chief Executive Officer & Senior Medical Advisor
Craig Paddock Chief Financial Officer
Laird Forrest Ph.D Founder, Chief Operating Officer and Board Member
Chad Groer Ph.D Chief Scientific Officer
You’re viewing 4 of 5 executive team members. Get the full list »

HylaPharm Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

HylaPharm Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Kansas Bioscience Authority Government Minority 000 0000 000000 0
To view HylaPharm’s complete investors history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »